Related Experiment Video
Updated: Jun 28, 2026

Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
Successful treatment of heart failure with devices requires collaboration
Karl Swedberg1, John Cleland, Martin R Cowie
1Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden. karl.swedberg@gu.se
Insights
Implanted cardiac resynchronisation therapy (CRT) and implantable cardioverter defibrillators (ICD) improve outcomes in heart failure patients. Underuse persists due to guideline adherence issues, necessitating improved collaboration and education for better patient care.
Area of Science:
- Cardiology
- Medical Devices
- Heart Failure Management
Background:
- Cardiac resynchronisation therapy (CRT) and implantable cardioverter defibrillators (ICDs) are proven to enhance survival and reduce morbidity in select chronic heart failure (CHF) patients.
- Evidence for device therapy in specific subgroups, like NYHA Class I or IV heart failure with reduced ejection fraction, or modest QRS prolongation, remains limited.
- Despite established benefits, a significant gap exists between eligible patients and those receiving these life-saving device therapies.
Purpose of the Study:
- To highlight the underutilization of CRT and ICDs in chronic heart failure (CHF) management.
- To identify barriers to device therapy adoption, including healthcare professional adherence to guidelines.
- To advocate for improved collaboration among specialists and structured approaches to optimize device therapy delivery.
Main Methods:
- Review of current evidence on CRT and ICD efficacy in chronic heart failure (CHF).
- Analysis of reasons for underuse of device therapies in eligible patient populations.
- Discussion of strategies to improve guideline adherence and patient access to device therapy.
Main Results:
- CRT and ICDs offer survival and morbidity benefits for specific CHF patient groups.
- Limited evidence exists for device therapy in certain patient subgroups, contributing to hesitancy.
- A minority of eligible CHF patients currently receive recommended device therapies, indicating underuse.
Conclusions:
- Underuse of CRT and ICDs in CHF is a significant issue, partly due to poor guideline adherence.
- Enhanced collaboration between heart failure specialists, electrophysiologists, and primary care physicians is crucial.
- A structured, collaborative approach is needed to improve care, reduce mortality and morbidity, and increase cost-effectiveness.
Abstract:
Implanted biventricular pacemakers (cardiac resynchronisation therapy, CRT) with or without implantable cardioverter defibrillators (ICD) improve survival and morbidity in some patients with chronic heart failure (CHF) who are optimally treated with pharmacologic agents according to current guidelines. Correspondingly, ICDs improve survival. However, there is only limited evidence for device treatment in certain patient subgroups, such as the impact of ICD on outcomes in patients with reduced ejection fraction in New York Heart Association (NYHA) Class I or IV heart failure. Similarly, limited evidence exists for CRT in patients with only modest QRS prolongation or only modestly reduced ejection fraction. Despite evidence for a beneficial effect of device therapy in CHF, only a minority of eligible patients are currently offered these options. Multiple reasons contribute to the underuse of these potentially life-saving therapies. A lack of adherence to guidelines by health care professionals is an important barrier. Clearly, efforts should be made to improve the standard of care and to familiarise all physicians involved in managing CHF patients with the indications and potential efficacy of these devices. Increased collaboration between structured heart failure care and pacemaker clinics as well as between electrophysiologists, heart failure clinicians, and primary care physicians is required. Such team collaborations should lead to improved care with reduced mortality and morbidity and increased cost effectiveness. Treatment strategy should be based on a structured approach tailored to local practice and national priorities.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Heart Failure V: Medical Management
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure VII: Nursing Interventions

